NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
14 nov. 2021 15h59 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first Australian patient has been dosed in the...
The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer
20 avr. 2021 10h32 HE
|
Telix Pharmaceuticals Limited
BRUSSELS, Belgium and MELBOURNE, Australia, April 20, 2021 (GLOBE NEWSWIRE) -- The Oncidium Foundation, a non-profit organisation created to promote and support the development of...
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
30 mars 2021 18h02 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with...
Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
16 févr. 2021 01h05 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
24 sept. 2020 07h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
23 sept. 2020 19h30 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
29 mai 2020 08h00 HE
|
Harpoon Therapeutics
The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts. Initial safety data showed that HPN424 is generally...
Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
06 mai 2020 16h05 HE
|
Harpoon Therapeutics
Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at...
Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
30 avr. 2020 20h14 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
Harpoon Therapeutics Appoints Two New Members to Its Board of Directors
01 avr. 2020 07h30 HE
|
Harpoon Therapeutics
Andrew R. Robbins, former Chief Operating Officer, Array BiopharmaDr. Joseph S. Bailes, former President of American Society of Clinical Oncology (ASCO) SOUTH SAN FRANCISCO, Calif., April 01, 2020 ...